Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
نویسندگان
چکیده
INTRODUCTION Since introduction of BRAF and MEK inhibition therapy, there has been a significant improvement in response rates, overall survival, and progression-free disease in melanoma patients. Combined BRAF and MEK inhibition, compared with BRAF inhibition alone, has shown to delay the emergence of resistance in patients suffering from BRAF V600emutated advanced melanoma. It has become the standard of care in patients carrying this mutation. Several mechanisms of resistance to BRAF and MEK inhibition have been shown. Reactivation of the mitogen-activated protein kinase pathway is the major trigger in more than two-thirds of tumors.
منابع مشابه
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases
To compare BRAF V600E status of primarymelanoma and brainmetastases to assess for discordance by cross-sectional study, and to evaluate clinical implications on BRAF inhibitor therapy. Brain metastases are common in patients with advanced melanoma. Between 40% and 60% of melanomas demonstrate BRAF mutations, BRAF V600E being most common. Selective BRAF inhibitor therapy has shown improvement in...
متن کاملBRAF/MEK Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions.
BACKGROUND BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma. However, these regimens are associated with adverse events (AEs) that may lead to unnecessary drug modifications and discontinuations or potentially serious sequelae. In addition, drug-drug interactions (DDIs) may result in AEs or altered therapeutic efficacy. . OBJECT...
متن کاملInvolution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
IMPORTANCE Eruptive melanocytic nevi (EMN) are characterized by the sudden onset of numerous melanocytic nevi and have been traditionally described in the setting of immunosuppression. Selective BRAF inhibitors such as vemurafenib cause multiple cutaneous adverse effects, including the formation of cutaneous squamous cell carcinoma, as well as EMN. We describe the first reported case, to our kn...
متن کاملNew developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due to paradoxical activation of the mitogen-activated protein kinase pathway. Combining selective BRAF and MEK inhibition, such as the BRAF inhib...
متن کاملTrametinib: a MEK inhibitor for management of metastatic melanoma
This review presents the current data on the efficacy and safety of the selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in patients with metastatic BRAF V600-positive melanoma. The pharmacological, safety, and efficacy data come from the Phase I, II, and III studies of trametinib monotherapy, as well as those in combination with the BRAF inhibitor da...
متن کامل